Bioventus/Seikagaku Extend SUPARTZ FX Distribution Agreement

Bioventus extended its agreement to exclusively distribute Seikagaku's SUPARTZ FX™ in the U.S. through May 2028. The hyaluronic acid-based product treats knee osteoarthritis pain through a 5-injection regimen.

SUPARTZ FX complements Bioventus' joint fluid treatments HA GELSYN-3™ (3-injection) and DUROLANE® single-injection HA—the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us